Institutional shares held 194 Million
564K calls
331K puts
Total value of holdings $13.5B
$39.4M calls
$23.1M puts
Market Cap $15.6B
222,431,008 Shares Out.
Institutional ownership 87.01%
# of Institutions 697


Latest Institutional Activity in INCY

Top Purchases

Q2 2025
Swedbank Ab Shares Held: 611K ($42.8M)
Q2 2025
Perpetual LTD Shares Held: 22.1K ($1.55M)
Q2 2025
Sivia Capital Partners, LLC Shares Held: 12.1K ($845K)
Q2 2025
Krilogy Financial LLC Shares Held: 17.9K ($1.25M)
Q2 2025
Baader Bank Aktiengesellschaft Shares Held: 6.32K ($442K)

Top Sells

Q2 2025
Sovran Advisors, LLC Shares Held: 11.5K ($805K)
Q2 2025
Mn Services Vermogensbeheer B.V. Shares Held: 29.9K ($2.09M)
Q2 2025
Pallas Capital Advisors LLC Shares Held: 38K ($2.66M)
Q2 2025
Diversified Trust CO Shares Held: 30.2K ($2.11M)
Q2 2025
North Crest Asset Manangement, LLC Shares Held: 11.3K ($794K)

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.


Insider Transactions at INCY

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
571K Shares
From 24 Insiders
Grant, award, or other acquisition 554K shares
Exercise of conversion of derivative security 16.2K shares
Sell / Disposition
245K Shares
From 18 Insiders
Payment of exercise price or tax liability 126K shares
Open market or private sale 119K shares

Track Institutional and Insider Activities on INCY

Follow INCYTE CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells INCY shares.

Notify only if

Insider Trading

Get notified when an Incyte Corp insider buys or sells INCY shares.

Notify only if

News

Receive news related to INCYTE CORP

Track Activities on INCY